ArticlePharmacoEconomics - open2022

Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer.

David Elsea et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.